Glivec (imatinib) 100 mg, 120 capsules, India, generic Order Glivec (imatinib) 100 mg, 120 capsules, India, generic. Medicine delivery from Europe within 4-5 days with storage conditions Order at +380996042415 via Viber or WhatsApp.
- We can ship by mail to any European country with a delivery time of 8-10 days. Only medications that do not require refrigeration possible shipping. Shipping costs are 40-50 euro, depending on the destination country.
Delivery time
- Originator medicines: 8-10 days
- Generic medicines: 8-10 days
- Bank transfer to the settlement account after receiving the order
Interchangeable drugs with the same active ingredient:
Alvotinib
Vinat
Vinat 100
Vinat-100-Health
Glivec
Imatib
Imatinib Actavis
Imatinib Grindeks
Imatinib Zentiva
Imatinib Medak
Imatinib-Teva
Myelofar
Neopax
Indications:
treatment of patients (adults and children) with newly diagnosed chronic myeloid leukemia;
treatment of patients (adults and children) with chronic myeloid leukemia in the phase blast crisis and acceleration phase and in the chronic phase after unsuccessful therapy with interferon alpha;
treatment of adult patients with newly diagnosed positive (with the presence of the Philadelphia chromosome (bcr-abl) in leukocytes) acute lymphoblastic leukemia as part of chemotherapy;
treatment of adult patients with acute lymphoblastic leukemia leukemia in the relapse stage or with persistent tolerance to chemotherapy as monotherapy;
treatment of adult patients with myelodysplastic / myeloproliferative diseases associated with activation of the platelet-derived growth factor receptor;
treatment of adult patients with systemic mastocytosis in the absence of D816B c-Kit mutations or with lack of data on c-Kit mutational status;
treatment of adults with hypereosinophilic syndrome and/or chronic esosinophilic leukemia;
treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant tumors of the digestive tract organs
treatment of patients with inoperable and/or metastatic dermatofibrosarcomas.
